Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prilosec OTC Name Will Create Consumer Confusion With Rx Drugs – Petition

This article was originally published in The Tan Sheet

Executive Summary

FDA should require that Prilosec OTC be sold under a different brand name to "reduce the risk of consumer confusion" resulting from extensive direct-to-consumer advertising for the Rx version of the drug, an Aug. 12 citizen petition says

Related Content

Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
OTC Prilosec Name Derivative Has Precedent In Other Rx Heartburn Switches
Prilosec OTC Patent Extension Request “Compels” Name Change – Mylan
Prilosec OTC Bioequivalence To Rx Version “Has No Impact” – P&G
Mylan Says OTC, Rx Prilosec Not Bioequivalent In Study
Prilosec OTC Formulation Targeted In Mylan Labs Suit
Prilosec OTC Brandname Defended By P&G In Response To Petition
Prilosec OTC Soothes P&G First Quarter Forecast As Early Shipments Rollout
Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices
Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts